In addition, some recent randomized studies investigated that sodium–glucose cotransporter 2 (SGLT2) inhibitors could significantly reduce the risk of clinically relevant renal outcomes including loss of kidney function, eGFR decline, worsening of albuminuria, new ESRD, death from renal causes and/or a renal composite outcome in patients with type 2 diabetes (T2D). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.